Enliven Therapeutics, Inc. - Common Stock (NQ:ELVN)

45.72 -1.25 (-2.67%)

Delayed Quote Updated: 12:05 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Enliven Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >

What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130% ↗

June 27, 2026

This Boulder biotech advancing cancer drugs saw a notable insider sale amid strong 1-year stock gains and early clinical progress.

Via The Motley Fool

Topics Regulatory Compliance

What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally ↗

June 27, 2026

Focused on cancer therapies, this Boulder-based biotech reported significant insider selling amid a year of sharp share price gains.

Via The Motley Fool

Topics Regulatory Compliance

Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN? ↗

June 24, 2026

This clinical-stage biotech advancing cancer therapies reported a notable insider sale as its lead candidates progress in early trials.

Via The Motley Fool

Topics Regulatory Compliance

Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors. ↗

June 01, 2026

This oncology-focused biotech, advancing kinase inhibitors for cancer, reported a notable insider sale amid strong one-year stock gains.

Via The Motley Fool

Topics Regulatory Compliance

This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗

May 31, 2026

This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform.

Via The Motley Fool

Topics Regulatory Compliance

Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120% ↗

May 13, 2026

This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates in early-stage clinical trials.

Via The Motley Fool

Topics Regulatory Compliance

Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company ↗

May 13, 2026

This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally ↗

May 13, 2026

This clinical-stage biotech develops monoclonal antibody therapies targeting psoriasis and other immunology indications.

Via The Motley Fool

Topics Regulatory Compliance

Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million ↗

March 28, 2026

This Boulder-based biotech, developing targeted cancer therapies, reported a notable insider sale as Phase 1 trials advance for key drug candidates.

Via The Motley Fool

Topics Regulatory Compliance

Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k ↗

February 01, 2026

The Chief Scientific Officer of this biopharmaceutical company sold 20,000 shares in mid-January 2026, amid the company's stock rising 71% throughout the month.

Via The Motley Fool

Topics Regulatory Compliance

The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff

January 12, 2026

Issued on behalf of Oncolytics Biotech Inc.

From Equity Insider

Via GlobeNewswire

S&P 500, Nasdaq Futures Waver Ahead Of Supreme Court Ruling On Trump Tariffs: Why OPEN, ACON, FLYX, OSCR Are Trending After-Hours ↗

January 08, 2026

Via Stocktwits

Topics Government Stocks

Here are the top movers in Thursday's session. ↗

January 08, 2026

Via Chartmill

ELVN Stock Shot Up 60% Today – What’s Driving The Rally? ↗

January 08, 2026

The company reported positive initial data from its ongoing Phase 1b clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia.

Via Stocktwits

These stocks are gapping in today's session ↗

January 08, 2026

Via Chartmill

Resemble AI Unleashes Chatterbox Turbo: A New Era for Open-Source Real-Time Voice AI

December 15, 2025

The artificial intelligence landscape, as of December 15, 2025, has been significantly reshaped by the release of Chatterbox Turbo, an advanced open-source text-to-speech (TTS) model developed by...

Via TokenRing AI

Topics Artificial Intelligence Fraud Hacking

With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗

December 03, 2025

One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.

Via The Motley Fool

Topics Regulatory Compliance

Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗

December 03, 2025

This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.

Via The Motley Fool

Topics Regulatory Compliance

Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors ↗

December 03, 2025

One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch.

Via The Motley Fool

Topics Regulatory Compliance

Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗

December 03, 2025

Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline?

Via The Motley Fool

Topics Regulatory Compliance

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 03, 2025

Via Benzinga

What's going on in today's pre-market session ↗

August 15, 2025

Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

Enliven Posts Loss Beat and Cash Surge ↗

August 13, 2025

Via The Motley Fool

Topics Intellectual Property

Meta To Rally Around 3%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

July 02, 2025

Via Benzinga

Enliven Short Interest Falls To 14-Month Low After Leukemia Trial Data, Goldman Initiates With ‘Buy’ ↗

June 23, 2025

Ortex data shows short interest in Enliven Therapeutics had hovered between 24% and 29% since October 2023.

Via Stocktwits

12 Health Care Stocks Moving In Friday's Intraday Session ↗

June 13, 2025

Via Benzinga

Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

April 08, 2025

Via Benzinga

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

October 31, 2024

Via Benzinga

Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

October 04, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst ↗

September 09, 2024

HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant...

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.